Previous CEO and Current Director of Allied Healthcare International Joins Global Med Technologies(R), Inc.'s Board
April 03 2006 - 10:00AM
PR Newswire (US)
DENVER, April 3 /PRNewswire-FirstCall/ -- Global Med Technologies,
Inc. (OTC:GLOB) (BULLETIN BOARD: GLOB) , announced today that Sarah
Ladd Eames has joined Global Med's Board of Directors as an
independent board member, Chairperson of the Company's Compensation
Committee, and a member of the Company's Audit Committee. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO ) Ms.
Eames comes to the Global Med Board with a wealth of health care
and business experience. Previously serving as Allied Healthcare
International's (NASDAQ:AHCI) CEO, President and Chief Operating
Officer, Ms. Eames is currently on the board of the $350 million
health care company. Ms. Eames stated, "I am both pleased and
honored to be on the Board of Global Med Technologies. Global Med
is a very exciting, rapidly growing medical software company to
which I believe I can make a substantial contribution." Michael I.
Ruxin, M.D., Global Med's Chairman and CEO, commented, "Sarah
Eames' credentials, with her specific, broad-based international
experience, and her prior management positions at Johnson &
Johnson, Apria Healthcare Group, Abbey Healthcare Group, and Baxter
Travenol, will add immense value to the Company as it expands
globally. On behalf of Global Med Technologies, I warmly welcome
Sarah to our Board of Directors." About Global Med Technologies,
Inc. Global Med Technologies, Inc. is an international e-Health,
medical information technology company, providing information
management software products and services to the healthcare
industry. Its Wyndgate Technologies division is a leading supplier
of information management systems to U.S. and international blood
centers and hospital transfusion centers. Current clients of
Wyndgate's products and services manage more than 3 million units
of blood, or over 22% of the U.S. blood supply, each year.
Wyndgate's products are also being implemented in Canada, the
Caribbean and sub-Sahara Africa. Together, the SafeTrace Tx(R)*
advanced transfusion management system and the SafeTrace(R) donor
management system provide Vein-to-Vein(R) tracking from donor
collection to patient transfusion. For more information about
Global Med's products and services, please call 800-WYNDGATE or
visit http://www.globalmedtech.com/, http://www.peoplemed.com/ and
http://www.wyndgate.com/. This news release may include statements
that constitute forward-looking statements, usually containing the
words "believe," "estimate," "project," "expects" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release. *Patent Pending
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D. of Global Med Technologies,
Inc., +1-303-238-2000; or Investor Relations, Paul Short, President
of Investment Strategies, LLC, +1-304-523-3252, for Global Med
Technologies, Inc. Web site: http://www.wyndgate.com/ Web site:
http://www.peoplemed.com/ Web site: http://www.globalmedtech.com/
Copyright